JPM — JPMorgan Chase & Co.

Sell-side is still constructive in aggregate - 31 buys vs. 2 sells, 'Buy' consensus, $373.18 consensus target (12 analysts, $376.67 recent average) implying ~11% upside - but the tape has sobered up. As of 2026-10-13 the stock was -4.71% over one month and -1.01% over three months despite +9.10% over six months, exactly the profile of a premium-multiple name that just missed on both lines. The offsets are real: core NII of $27.04B (+12.8% YoY), trading revenue +15% to $10.3B, dealmaking fees +14%, provisions -19% YoY to $2.74B, full-year total NII guidance raised to ~$106.2B, and a 10% dividend hike to $1.65/quarter. Net: bullish fundamentals, chastened near-term sentiment.

Revenue growth re-accelerated through 2026 off a soft 2025 base but is not a clean uptrend. YoY revenue growth went 3.2% (Q3'25) -> 3.9% (Q4'25) -> 6.9% (Q1'26) -> 17.9% (Q2'26) -> 6.0% (Q3'26). The Q2'26 print ($82.46B revenue, $21.2B net income, $7.70 EPS) is clearly anomalous - EPS nearly 47% above Q2'25's $5.24 - and Q3'26 snapped back to $5.57, still +9.9% YoY versus Q3'25's $5.07. Net margin has been remarkably stable at roughly 19-22% (Q3'26: 20.1%; Q3'25: 20.0%; Q2'26: 25.7%), and operating margin is only modestly better YoY (26.4% vs. 26.1%). Read this as stable-to-gently-improving, not accelerating: the underlying business is compounding revenue mid-single-digits with steady margins, and the headline volatility is coming from capital-markets seasonality plus a one-off-looking Q2. One data caveat: FMP's revenue line for Q3'26 ($76.19B) is far above the $50.17B GAAP total revenue cited in the research brief, so FMP is likely using a broader/gross revenue definition - I have used FMP's series only for like-for-like directional comparison.

Fair-to-slightly-rich. As of 2026-10-13, JPM traded at 14.14x TTM P/E on given EPS of $24.63 (about 14.2x on my own sum of the last four diluted quarters, $23.84) versus a 5-year average P/E of 12.0x - roughly an 18% premium to its own history. P/S of 3.00x also sits above the 5-year average of 2.84x, and P/B of 2.43x is a full multiple for a bank, though it is defensible against a 15.7% ROE and ~20% ROTCE. Forward P/E is a more reasonable ~13.5x on next-FY consensus EPS of $24.97, and the PEG of 0.79 looks cheap only because it uses an aggressive growth input. Note the deterministic framework labels this 'Neutral vs. its own history'; I would describe it as a premium franchise priced at a premium multiple - you are not being paid for the quality, but you are not being badly overcharged either.

The key tension: consensus next-FY EPS of $24.97 is only ~4.7% above my trailing four-quarter figure of $23.84, and roughly 12% above the Q3'26 annualized run-rate of $22.28. So at ~13.5x forward, the market is not pricing in heroic growth - it is pricing in NII durability plus an IB/capital-markets rebound, and paying a 14x TTM multiple for it. That cuts both ways: the bar is low enough that a normal Q4 with the raised $106.2B NII guide intact could re-rate the stock back toward the $370s analyst targets, but a second consecutive revenue miss (or a 2027 NIM guide-down) would make 14x look expensive fast, because there is no deep-value cushion at 2.43x book. Practical read: the current price already assumes execution, so buy on proof of stabilization, not on faith.

Range-bound consolidation inside an intact longer-term uptrend, as of 2026-10-13. RSI(14) of 48.92 is dead neutral - no oversold bounce setup and no overbought risk. Price at $337.57 is 0.45% above the 20-day SMA (~$336, derived), 2.89% below the 50-day SMA (~$348, derived), and 5.34% above the 200-day SMA (~$320, derived), which means the short-term trend has rolled over while the primary trend is still up. With the 52-week range at $279.10-$366.50, the stock is 21% off its low and 7.9% off its high - a mid-range position. Entry implication: no technical urgency to buy here; the higher-probability accumulation zone is a retest of the 200-day near ~$320, while a decisive reclaim of the 50-day near ~$348 would confirm the post-earnings dip is being bought.

• Rate path and NII durability: elevated rates support JPM's raised ~$106.2B total NII guide, but 2027 net interest margin is the swing question if deposit costs stay sticky while policy rates fall.
• Credit normalization: card service net charge-offs projected around 3.2% and provisions of $2.74B (-19% YoY) show resilience, but consumer credit is a late-cycle watch item tied to unemployment.
• Capital and regulation: Basel endgame / G-SIB surcharge and the stress capital buffer directly determine buyback capacity - management already scaled back repurchases to fund franchise investment.
• Capital markets cycle: the tech/AI IPO and M&A pipeline is the primary driver of CIB fee acceleration (dealmaking fees +14% YoY, trading +15% to $10.3B).
• Macro-financial risk backdrop flagged by management: persistent fiscal deficits, sticky inflation, elevated asset valuations, and shifting geopolitics - JPM is the natural flight-to-quality beneficiary in a stress event but would take mark-to-market hits first.

• Q4 2026 earnings on 2027-01-14 - the first clean read on whether the Q3 revenue miss was noise or the start of a trend, plus the initial 2027 NII/NIM guide.
• Continuation of the corporate advisory and IPO pipeline, particularly technology and AI-related listings, driving CIB fees and trading revenue higher.
• Further capital return: the 10% dividend increase to $1.65/quarter (declared September 2026) and any resumption of the share repurchases that were scaled back in Q3 2026.
• Management appearances including the BancAnalysts Association of Boston Conference, where commentary on NII, expenses, and credit could move the stock.
• Credit quality - a benign provision trajectory (currently $2.74B, -19% YoY) would validate the premium multiple.

• Negative operating leverage: FY2026 adjusted expenses were guided up to ~$108.6B from $107.5B, and expense growth outrunning revenue would compress both margins and the multiple.
• A second consecutive revenue/EPS miss would be taken badly at 2.43x book and ~14x earnings, where there is little valuation cushion.
• Credit deterioration: card net charge-offs near 3.2% leaving little room for error if the consumer weakens or unemployment rises.
• 2027 net interest margin risk if deposit repricing lags rate cuts or money-market fund competition pushes funding costs higher.
• Regulatory/legal risk: higher capital surcharges or an unfavorable Basel endgame outcome would pressure ROTCE and buyback capacity - plus Dimon's flagged macro risks (fiscal deficits, geopolitics, elevated asset valuations).

JPMorgan is arguably the best-run large bank in the world - 15.7% ROE, 21.9% net margin, a $106B+ NII run-rate, growing trading and advisory franchises, and a fortress balance sheet - but it is priced accordingly at 14.1x TTM earnings and 2.43x book versus its own 12.0x five-year average, and the Q3 2026 miss (EPS $5.57 vs. ~$5.92; revenue $50.17B vs. $51.2-51.7B consensus) plus the raised $108.6B expense guide shows why a premium multiple and decelerating earnings is an uncomfortable combination. My read is fairly valued to modestly cheap, not a bargain: I calculate intrinsic value near $345 versus $337.57 as of 2026-10-13, implying roughly a 2% price upside plus the 1.86% dividend, before any re-rating. Own it for quality and balance-sheet safety, accumulate on pullbacks toward $320, but do not expect the double-digit annualized returns of the last two years to repeat from this multiple.

I used a justified-P/E approach: a 13.8x multiple applied to next-FY consensus EPS of $24.97, giving ~$344.6. The 13.8x is a deliberate middle ground between JPM's 12.0x five-year average P/E (which understates its current earnings power post-rate normalization and franchise scale) and the ~14x the market pays it today (which overstates the case given only mid-single-digit consensus EPS growth and a fresh revenue miss); it is also consistent with a Gordon-growth fair P/B of roughly 2.47x (ROE 15.7%, cost of equity ~9.5%, growth ~4.5%) on Q3 2026 book value per share of ~$139, which brackets $330-$345.